



Press Contact

Dr Barbara Domayne-Hayman
CEO, Stabilitech Ltd
bdh@stabilitech.com
+ 44 (0)7771 635450

FOR IMMEDIATE RELEASE

24th August 2010

Stabilitech Ltd

("Stabilitech" or "the Company")

STABILITECH SIGNS \$4 MILLION CONTRACT WITH DEFENSE THREAT REDUCTION AGENCY

Stabilitech Ltd, the protein stabilisation company, announced today that it has signed a contract with the United States Defense Threat Reduction Agency (DTRA), an agency within the United States Department of Defense. The contract is to fund a programme of work to stabilise two novel biodefense vaccines using Stabilitech's proprietary vaccine stabilisation technology. Over the contract period, funding could amount to a total of \$4 million over three years.

Stabilitech will apply its proprietary formulation principles to stabilise both adenovirus vectored and adjuvanted vaccines, being developed for potential use against a key bacterial pathogen target. The stated goal of the DTRA is to find technologies that will successfully allow the stockpiling of key biodefense vaccines by protecting vaccines against both heat and freeze damage in addition to enabling ambient temperature storage.

Dr Barbara Domayne-Hayman, Stabilitech's CEO, said: "We are very pleased to have been selected by DTRA to work on these key projects for the US Department of Defense. We believe that the work which will demonstrate the broad applicability of our stabilisation technology and enable the DTRA to achieve its goals for these important biodefense vaccines. In addition, this non-dilutive funding is important as Stabilitech continues to grow and will supplement our 2009 fund-raising."

-ENDS-

Stabilitech Ltd

Dr Barbara Domayne-Hayman, CEO

+44 7771 635450

bdh@stabilitech.com

Notes for editors:

About Stabilitech

Stabilitech is a private London based company which operates from the Imperial College Incubator. The Company was founded by Dr Jeff Drew who acts as the Chief Scientific Officer. Research on the stabilization of vaccines started in 2004 and has developed into a novel proprietary technology for the stabilization of vaccines, biopharmaceuticals and other protein products.

Stabilitech's business model is to establish partnerships with major pharmaceutical and biotechnology companies, as well as not-for-profit organizations with a focus on global health, to whom it will license the technology for commercialisation.

In March 2009, Stabilitech raised £3.3 million, mainly from business angel investors.

Technology and Benefits:

Stabilitech's platform technology targets the following benefits:



Press Contact

Dr Barbara Domayne-Hayman
CEO, Stabilitech Ltd
bdh@stabilitech.com
+ 44 (0)7771 635450

- Protection of biopharmaceutical or vaccine efficacy where refrigeration standards are less rigorous – which include the increasing use of biopharmaceuticals in primary care settings and/or in patients' homes, as well as in developing countries.
- Stabilisation of unstable viruses and proteins, enabling a wider range of vaccines than is currently available.
- Greatly facilitated stockpiling, rapid deployment and logistics for thermo-stable vaccines in the field, including in harsh conditions with elevated ambient temperatures.
- A longer shelf life should be established, once a longer term of storage of bulk and final product is possible.
- Loss of entire vaccine batches due to temperature variations/maintenance during storage or distribution should become avoidable. Transportation and storage costs could be dramatically reduced.
- Competitive advantage via a differentiation platform for 'next generation' products, including the potential for extension of intellectual property protection, which is of interest both to major pharmaceutical companies and to bio-similars producers.

Stabilitech's approach involves the addition of carefully selected excipients at optimised concentrations and ratios, followed by freeze drying. Application of the technology fits into existing standard manufacturing procedures, thus involving minimal disruption. The excipients used have all been previously used in clinical settings, and all are relatively inexpensive and readily available.

About Defense Threat Reduction Agency:

The Defense Threat Reduction Agency (DTRA) was founded in 1998 to integrate and focus the capabilities of the Department of Defense that address the weapons of mass destruction (WMD) threat. The mission of the DTRA is to safeguard America and its allies from WMD (e.g. chemical, biological, radiological, nuclear, and high yield explosives) by providing capabilities to reduce, eliminate, and counter the threat, and mitigate its effects. Under DTRA, Department of Defense resources, expertise and capabilities are combined to ensure the United States remains ready and able to address the present and future WMD threats. For more information on DTRA, visit www.dtra.mil/.